Ascendis Pharma swings to Q2 profit on revenue doubling, PRV sale

Ascendis Pharma A/S

13/08/2026 12:50

Overview
Denmark-based biopharma's Q2 product revenue rose 105% yr/yr, driven by TransCon product demand
Company posted net profit of €207 mln, reversing prior-year loss
Growth supported by YORVIPATH sales and €158 mln PRV sale

Outlook
Company expects EMA decision on YUVIWEL in Q4 2026
Ascendis plans to initiate Phase 3 trial of TransCon CNP for hypochondroplasia in H2 2026
Company expects to start Phase 3 trial of TransCon CNP + TransCon hGH in pediatric achondroplasia in Q4 2026

Result Drivers
YORVIPATH DEMAND - Co said Q2 revenue growth was driven by consistent new patient demand for YORVIPATH in the U.S. and expansion in over 35 countries
PRV SALE - Q2 operating profit benefited from €158 mln in cash from sale of Rare Pediatric Disease Priority Review Voucher
COMMERCIAL EXPANSION - Higher selling, general, and administrative expenses due to continued impact from commercial expansion, including global launch activities

Company press release: ID:nGNX8rFS7p

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
 
EUR 339.30 mln
 
Q2 EPS
 
EUR 2.83
 

Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 20 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 32 three months ago

Reuters Recommended Reads
Aug 10 - Rocket Pharmaceuticals posts Q2 profit helped by PRV sale
Aug 13 - Denmark's Zealand Pharma H1 revenue, profit fall sharply
Aug 12 - Kura Oncology Q2 product revenue rises 57% on KOMZIFTI uptake

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)